ESN Cleer
Manufacturing · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Malvern, Victoria, 3144, AustraliaPhone Number
+61 423748100Website
www.cleer.com.auRevenue
<$5 MillionIndustry
About ESN Cleer
ESN Cleer is dedicated to the repurposed drug development for orphan indications in cardiomyopathies, focusing on rare diseases that lack specific treatments. The company aims to address significant causes of heart failure, which affect a wide range of the cardiovascular disease population. By targeting these high-mortality risk conditions, ESN Cleer seeks to improve the quality of life for affected individuals. Their mission underscores the importance of innovative solutions in the healthcare sector.Explore more
ESN Cleer Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to ESN Cleer
Compare insights from companies similar to ESN Cleer, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
ESN Cleer
<$5M
1-10
Private
-
2017
Gd
Gustav de BruinChief Operating Officer & Program Director, Research & Development
ESN Cleer Tech Stack
A closer look at the technologies used by ESN Cleer
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding ESN Cleer
Sign Up For FreeTo access detailed company insights
ESN Cleer is dedicated to the repurposed drug development for orphan indications in cardiomyopathies, focusing on rare diseases that lack specific treatments. The company aims to address significant causes of heart failure, which affect a wide range of the cardiovascular disease population. By targeting these high-mortality risk conditions, ESN Cle... Read More
